Background
==========

On April 15^th^and 17^th^2009, a novel swine-lineage influenza A (H1N1/2009) infection was reported to the World Health Organisation (WHO) by the Centers for Disease Control and Prevention (CDC) in Atlanta. The virus was detected in two children from adjacent counties in southern California presenting with febrile respiratory illness \[[@B1],[@B2]\]. These cases were not epidemiologically linked and neither child had exposure to swine. Subsequent phylogenetic characterisation of H1N1/2009 from the U.S. index case (A/California/04/2009) showed that the virus had a unique genome composition that had not been previously identified. Six genes (PB2, PB1, PA, HA, NP, and NS) were similar to viruses previously identified in triple-reassortant swine influenza viruses in North American pigs. The remaining two genes (NA and M) were derived from Eurasian swine influenza viruses. This particular gene constellation had never been previously identified in humans or other reservoirs.

Following the original identification of Influenza A/H1N1/2009 in the United States, sustained human-to-human transmission was seen in other countries, and on June 11, 2009, the WHO declared that the virus was responsible for the first influenza pandemic of the 21st century \[[@B3]\].

The first cases of H1N1/2009 in Scotland were detected at the end of April 2009 in a couple returning from their honeymoon in Mexico \[[@B4],[@B5]\]. The initial public health response to the outbreak was a containment exercise aimed at preventing the spread of infection, detecting cases and taking action to prevent these cases from infecting others \[[@B6]\]. The exercise was initially based on clinical and epidemiological criteria (table [1](#T1){ref-type="table"}). Patients who met these criteria were immediately given treatment and isolated while a rapid real time reverse transcriptase polymerase chain reaction (rtRT-PCR) for H1N1/2009 was initiated. Contact tracing was undertaken in order to treat those who had been in contact with confirmed cases. Soon after the first detections, person to person transmission was confirmed as having occurred in Scotland. Consequently, the epidemiological criteria were no longer useful and the containment exercise was then based on clinical criteria only. Testing continued to be carried out during this period.

###### 

The clinical and epidemiological criteria for the screening and testing of H1N1/2009 cases

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Clinical Criteria                                                                                                                                Epidemiological criteria
  ------------------------------------------------------------------------------------------------------------------------------------------------ -----------------------------------------------------------------------------------------------------------------
  Fever ***or***history of fever **[and]{.ul}**flu-like illness **[or]{.ul}**severe life threatening illness suggestive of an infectious process   Onset of illness within 7 days of travelling to an area where sustained transmission of H1N1/2009 is occurring\
                                                                                                                                                   Contacts with a probable/confirmed case of H1N1/2009

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

During the outbreak period (April-July 2009) the West of Scotland Specialist Virology Centre (WoSSVC) tested 16 264 clinical samples for H1N1/2009 (Figure [1](#F1){ref-type="fig"}). Of these, only 1516 were positive (9% overall for the period of April-July; range 5-10% per month). Consequently, the clinical diagnosis was found to be wrong in the majority of cases.

![**H1N1 outbreak in the spring/summer 2009**.](1471-2334-11-192-1){#F1}

A large number of viral infections, drugs and other diseases can cause disease presentations similar to those presented in Table [1](#T1){ref-type="table"}. This is especially true for respiratory pathogens. The present study sought to determine what respiratory pathogens were diagnosed as cases of H1N1/2009 during the containment phase.

Methods
=======

Background to the respiratory service in place during April-July 2009
---------------------------------------------------------------------

During April-July 2009 all respiratory samples submitted from patients with a clinical diagnosis of H1N1/2009 (as stated on the specimen request form), were initially tested using a universal influenza A real time rtRT-PCR assay and a H1N1/2009 specific real time rtRT-PCR assay \[[@B7]\].

If the sample was negative on these tests and was from a hospitalised patient, a patient deemed at risk of severe respiratory infection (e.g. an immunocompromised or a pregnant patient), or a patient attending GP services taking part in local or national surveillance schemes, a full respiratory screen was carried out (see below for details regarding the full respiratory screen). Note that this information was derived from the sample request form.

With regard to (i) samples from GP services not taking part in the surveillance schemes mentioned above, (ii) follow-up samples from known H1N1/2009 positive patients, and (iii) samples from patients with no clinical/setting details, only the initial screening test was conducted.

Samples
-------

To determine which respiratory pathogens had been misdiagnosed as H1N1/2009, we examined the results of 3247 samples which had been given a full respiratory screen during the period April-July 2009.

All had been clinically diagnosed as having H1N1/2009, and all were found to be H1N1/2009 negative. The samples submitted included gargles, throat swabs, nasal swabs, nasopharyngeal aspirates, sputums, and endotracheal secretions. The number collected each month and the age of the patients are shown in Table [2](#T2){ref-type="table"}. Binomial 95% confidence intervals are shown for each age group.

###### 

Patient groups per month of the 3247 samples

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
              April        May                               June         July                             Total                                                                                                      
  ----------- ------------ --------------------------------- ------------ -------------------------------- ------------ --------------------------------- ------------ --------------------------------- ------------ ---------------------------------
              **Number**   **% (95% confidence interval)**   **Number**   **%(95% confidence interval)**   **Number**   **% (95% confidence interval)**   **Number**   **% (95% confidence interval)**   **Number**   **% (95% confidence interval)**

                                                                                                                                                                                                                      

  \< 1 yrs    101          16.7 (13.8-19.9%)                 78           12.1 (9.7-14.8%)                 91           11.8 (9.6-14.2%)                  124          10.1 (8.5-11.9%)                  394          12.1 (11-13.3%)

                                                                                                                                                                                                                      

  1-5 yrs     104          17.2 (14.2-20.4%)                 95           14.7 (12-17.7%)                  129          16.7 (14-19.5%)                   143          11.7 (9.9-13.6%)                  471          14.5 (13.3-15.7%)

                                                                                                                                                                                                                      

  6-16 yrs    49           8.1 (6-10.6%)                     50           7.7 (5.8-10.1%)                  90           11.6 (9.5-14.1%)                  113          9.2 (7.7-11%)                     302          9.3 (8.3-10.4%)

                                                                                                                                                                                                                      

  17-64 yrs   266          44 (40-48%)                       315          48.7 (44.7-52.6\                 378          48.8 (45-52.4%)                   693          56.5 (53.7-59%)                   1652         50.9 (49.1-52.6%)
                                                                          %)                                                                                                                                          

                                                                                                                                                                                                                      

  \> 65 yrs   84           13.9 (11.2-16.4%)                 109          16.8 (14-20%)                    87           11.2 (9.1-13.7%)                  148          12.1 (10.3-14%)                   428          13.2 (12-14.4%)

                                                                                                                                                                                                                      

  Total       605                                            647                                           774                                            1226                                           3247         
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Laboratory Methods
------------------

Total nucleic acid was extracted from respiratory specimens using QIAamp Viral RNA kit (Qiagen, Crawley, United Kingdom) according to the manufacturer\'s instructions.

Real-time RT-PCR was carried out in order to detect influenza A (a generic assay and a H1N1/2009 specific assay \[[@B7]\]), B and C, RSV, rhinovirus, parainfluenza 1-4, human metapneumovirus, coronavirus (229E, NL63, HKU1 and OC43), adenovirus, and *Mycoplasma pneumoniae*.

The oligonucleotide primers and probe (TIB-MOLBIOL, Berlin, Germany) are outlined in Table [3](#T3){ref-type="table"}. The primers and probes for the influenza A generic assay and the H1N1/2009 specific assay are described elsewhere \[[@B7]\]. These assays have been developed by the WOSSVC and used as the frontline test for respiratory samples since 2005. All assays have been shown to be sensitive and specific by in-house development procedures and via participation in numerous external quality assessment schemes (EQA), including those provided by the WHO, the Health Protection Agency (HPA), and Quality Controls for Molecular Diagnostics (QCMD).

###### 

Primer and probe sequences for the respiratory multiplex rtPCR

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Multiplex   Virus Target                    Target Gene               Forward primer sequence                   Reverse primer sequence          Probe sequence
  ----------- ------------------------------- ------------------------- ----------------------------------------- -------------------------------- --------------------------------------------------
  1           Influenza B                     NS                        ATGATCTTACAGTGGAGGATGAAGAA                CGAATTGGCTTTGRATGTCCTT           **CY5-**ATGGCCATCGGATCCTCAAYTCACTCT-**BHQ**

                                                                                                                                                   

              Influenza C                     Matrix                    GGCAAGCGACATGCTGAAYA                      TCCAGCTGCYTTCATTTGCTTT           **VIC**-CTCTTCCTTCTGATTTTTTCAAA-**MGBNFQ**

                                                                                                                                                   

  2           Mycoplasma pneumoniae           Cytadhesin P1 (P1) gene   AAGCAGGAGTGACGGAAACAC                     CACCACATCATTCCCCGTATT            **CY5-**CTCCACCAACAACCTCGCGCCTA-BHQ

                                                                                                                                                   

              Human metapneumovirus A         Fusion                    GCYGTYAGCTTCAGTCAATTCAA                   TCCAGCATTGTCTGAAAATTGC           **VIC**-CAACATTTAGAAACCTTCT-**MGBNFQ**

                                                                                                                                                   

              Human metapneumovirus B         Fusion                    GCYGTYAGCTTCAGTCAATTCAA (Common with A)   GTTATCCCTGCATTGTCTGAAAACT        **VIC**-CGCACAACATTTAGGAATCTTCT-**MGBNFQ**

                                                                                                                                                   

              Parainfluenza virus 1           HN                        GTGATTTAAACCCGGTAATTTCTCA                 CCTTGTTCCTGCAGCTATTACAGA         **FAM**-ACCTATGACATCAACGAC-**MGBNFQ**

                                                                                                                                                   

  3           Parainfluenza virus 2           HN                        ATGAAAACCATTTACCTAAGTGATGGA               CCTCCYGGTATRGCAGTGACTGAAC        **VIC**-TCAATCGCAAAAGC-MGBNFQ

                                                                                                                                                   

              Parainfluenza virus 3           HN                        CCAGGGATATAYTAYAAAGGCAAAA                 CCGGGRCACCCAGTTGTG               **FAM**-TGGRTGTTCAAGACCTCCATAYCCGAGAAA-**BHQ**

                                                                                                                                                   

              Parainfluenza virus 4           Fusion                    CAGAYAACATCAATCGCCTTACAAA                 TGTACCTATGACTGCCCCAAARA          **CY5**-CCMATCACAAGCTCAGAAATYCAAAGTCGT-**BHQ3A**

                                                                                                                                                   

  4           Human coronavirus 229E          Nucleocapsid              CAGTCAAATGGGCTGATGCA                      AAAGGGCTATAAAGAGAATAAGGTATTCT    **FAM**-CCCTGACGACCACGTTGTGGTTCA-\
                                                                                                                                                   **BHQ**

                                                                                                                                                   

              Human coronavirus OC43          Nucleocapsid              CGATGAGGCTATTCCGACTAGGT                   CCTTCCTGAGCCTTCAATATAGTAACC      **CY5**-TCCGCCTGGCACGGTACTCCCT- **BHQ**

                                                                                                                                                   

              Human coronavirus NL63          1a gene                   ACGTACTTCTATTATGAAGCATGATATTAA            AGCAGATCTAATGTTATACTTAAAACTACG   **VIC**-ATTGCCAAGGCTCCTAAACGTACAGGTGTT-**TAMRA**

                                                                                                                                                   

  5           Respiratory syncitial virus A   NP                        AGATCAACTTCTGTCATCCAGCAA                  TTCTGCACATCATAATTAGGAG           **FAM**-CACCATCCAACGGAGCACAGGAGAT-**BHQ**

                                                                                                                                                   

              Respiratory syncitial virus B   NP                        AAGATGCAAATCATAAATTCACAGGA                TGATATCCAGCATCTTTAAGTA           **FAM**-TTTCCCTTCCTAACCTGGACATA-**BHQ**

                                                                                                                                                   

              Rhinovirus                      5\'-UTR                   TGGACAGGGTGTGAAGAGC                       CAAAGTAGTCGGTCCCATCC             **VIC**-TCCTCCGGCCCCTGAATG-**TAMRA**

                                                                                                                                                   

              Adenovirus                      Matrix                    GCCACGGTGGGGTTTCTAAACTT                   GCCCCAGTGGTCTTACATGCACATC        **CY5**-TGCACCAGACCCGGGCTCAGGTACTCCGA-**BHQ**
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

All assays used the primers at a final concentration of 0.4 μM and the probe at 0.2 μM in a 15 μl reaction volume. One-step rtRT-PCR was performed on 6 μl of RNA extract with the Platinum One-step qRT-PCR kit (Invitrogen life technologies, Paisley, UK) on an ABI Prism 7500 SDS real-time platform (Applied Biosystems). The following thermal profile was used: a single cycle of reverse transcription for 15 min at 50°C, 2 min at 95°C for reverse transcriptase inactivation and DNA polymerase activation followed by 40 amplification cycles of 15 sec at 95°C and 34 secs at 60°C each (annealing-extension step). Data acquisition occurred at the annealing step of each cycle, and the threshold cycle (Ct) for each sample was calculated by determining the point at which the fluorescence exceeded the threshold limit.

Statistical Analysis
--------------------

The percentage detection rate for each pathogen was analysed monthly, and for the overall study period. Binomial 95% confidence intervals were also determined for each detection rate. A chi-squared test was used for any comparisons of two data sets.

Please note that ethical approval was not required for this paper as the samples were collected as part of routine diagnostic work.

Results
=======

Detection rate in all samples per month
---------------------------------------

Examination of the detection rate over the four-month period shows that respiratory pathogens were detected in 27.9% of all samples submitted (95% confidence interval, 26.3-29.5%) (Table [4](#T4){ref-type="table"}). Numerous pathogens were detected in the samples. The most commonly detected pathogen was rhinovirus which was detected in 8.9% of all samples tested (95% confidence interval, 7.9-9.9%), and was similarly detected in each of the months examined. Adenovirus was also commonly detected (3.5% (95% confidence interval, 2.9-4.2%). Parainfluenza 3 showed its typical activity. It was detected in 7.9% of all samples collected in April (95% confidence interval, 6-10%) with decreasing activity thereafter (1.9% in July (95% confidence interval, 1.2-2.8%))(p \< 0.001)). Interestingly, parainfluenza 1 (a pathogen normally associated with winter activity) was present in an unexpectedly large number of samples during this period (1.9% of all samples overall (95% confidence interval, 1.4-2.4%) and mirrored the increasing activity of H1N1/2009 (from 0.8% in April (95% confidence interval, 0-2%) to 3% in July (95% confidence interval, 2.1-4.1%) (p = 0.0054)). The detection rate for the remaining pathogens was low (\< 1.6%) and showed no particular pattern over the months examined.

###### 

Detection rate in all samples per month

                                April        May                June         July             Total                                                                      
  ----------------------------- ------------ ------------------ ------------ ---------------- ------------ ------------------ ------------ ---------------- ------------ ------------------
                                **Number**   **% (95% CI)**     **Number**   **% (95% CI)**   **Number**   **% (95% CI)**     **Number**   **% (95% CI)**   **Number**   **% (95% CI)**
                                                                                                                                                                         
  Influenza B                   1            0.2 (0-0.92)                                     1            0.1 (0-0.7)                                      2            
                                                                                                                                                                         
  Influenza C                   2            0.3 (0-1.2)                                                                                                    2            
                                                                                                                                                                         
  Parainfluenza 1               5            0.8 (0.-2)         2            0.3 (0-1.1)      18           2.3 (1-3.7)        37           3 (2.1-4.1)      62           1.9 (1.4-2.4)
                                                                                                                                                                         
  Parainfluenza 2               0                                                             1            0.1 (0-0.7)        4            0.3 (0-0.8)      5            
                                                                                                                                                                         
  Parainfluenza 3               48           7.9 (6-10)         42           6.5 (4.7-8.7)    21           2.7 (1.7-4.1)      23           1.9 (1.2-2.8)    134          4.1 (3.3-4.9)
                                                                                                                                                                         
  Parainfluenza 4               0                                                             3            0.4 (0-1.1)        3            0.2 (0-0.7)      6            
                                                                                                                                                                         
  Rhinovirus                    64           10.6 (8.24-13.3)   52           8 (6-10.4)       58           7.5 (5.7-9.6)      114          9.3 (7.7-11)     288          8.9 (7.9-9.9)
                                                                                                                                                                         
  Coronavirus                   11           1.8 (0.9-3.2)      9            1.4 (0-2.6)      5            0.6 (0-1.5)        5            0.4 (0-0.1)      30           0.9 (0.6-1.3)
                                                                                                                                                                         
  Adenovirus                    14           2.3 (1.2-3.9)      25           3.9 (2.5-5.7)    24           3.1 (2-4.6)        50           4.1 (3-5.3)      113          3.5 (2.9-4.2)
                                                                                                                                                                         
  Human metapenumovirus         6            1 (0.3-2.2)        15           2.3 (1.3-3.8)    17           2.2 (1-3.5)        15           1.2 (0.6-2)      53           1.6 (1.2-2.1)
                                                                                                                                                                         
  Respiratory syncitial virus   21           3.5 (2.1-5.3)      2            0.3 (0-1)        1            0.1 (0-0.7)        2            0.2 (0-0.5)      26           0.8 (0-1.2)
                                                                                                                                                                         
  M pneumoniae                  2            0.3 (0-1.2)                                      3            0.4 (0-1.1)        1            0.1 (0-0.5)      6            
                                                                                                                                                                         
  Enterovirus                   8            1.3 (0.6-2.6)      7            1.1 (0-2.2)      6            0.8 (0-1.6)        6            0.5 (0-1)        27           0.8 (0.5-1.2)
                                                                                                                                                                         
  Mixed                         20           3.3 (2-5)          9            1.4 (0.6-2.6)    21           2.7 (1.6-4.1)      28           2.3 (1.5-3.3)    78           2.4 (1.9-3)
                                                                                                                                                                         
  Overall                       202          33.4 (29.6-37.3)   168          26 (22.6-29.5)   198          25.6 (22.5-28.8)   337          27.5 (25-30.1)   905          27.9 (26.3-29.5)
                                                                                                                                                                         
  Total                         605                             647                           774                             1226                          3247         

Discussion and conclusions
==========================

This study highlights the problems of using a clinical algorithm to detect H1N1/2009 during a period of low incidence. We found that clinicians frequently misdiagnosed common respiratory pathogens as H1N1/2009 during the spring/summer outbreak in Scotland. This finding is similar to results found in a recent audit of patients hospitalised with clinically diagnosed H1N1/2009 in infectious disease units in Scotland \[[@B8]\].

The pathogens that were misdiagnosed as H1N1/2009 were, for the most part, those viruses expected to be encountered during the spring/summer months. Although all the pathogens included in the respiratory screen were detected on at least one occasion, rhinovirus was the most commonly detected pathogen. This is not a surprising finding, since rhinovirus is detected all the year round; moreover, it is recognised as a very common cause of the common cold and is increasingly being implicated in more severe clinical syndromes \[[@B9]\]. PF1, PF3, adenovirus and human metapneumovirus were also frequently detected.

An unexpected finding was the frequent detection of parainfluenza 1, a pathogen which is traditionally recognised as a winter pathogen. However, our data shows that there were numerous cases of parainfluenza 1 during April-July 2009, and these mirrored the activity of H1N1/2009. The unexpected summer activity of parainfluenza 1 mirrors that of parainfluenza 4 in 2008, which was also unexpectedly detected during the summer months (data not shown). This suggests that the epidemiology of established viruses, such as parainfluenza 1, should be re-examined in the light of new, more sensitive, molecular assays.

It should be noted that the majority (\~70%) of samples submitted to the laboratory were found to be negative by real time rtRT-PCR. By participation in various EQA schemes, the assays used by the laboratory have been shown to be highly sensitive. Consequently, the large number of negative results are unlikely to have been caused by the pathogens already tested for in the screen. However, the respiratory screen does not include an internal control. Consequently, false negatives due to inhibition may have occurred. Nevertheless, the number of samples affected is likely to be small, since a recent in-house audit found that inhibition occurs in \~1% of throat and nasal swabs submitted to our laboratory. Poor sampling may also have led to false negative results. However, as with the case of inhibition, the contribution of this factor is likely to be minimal.

We cannot rule out that the possibility that these samples may have contained other respiratory pathogens not currently included in the respiratory screen (e.g. boca, HKU1 or bacterial respiratory pathogens). In future, the use of a larger testing panel either by further developing the existing service or by using an alternative method (e.g. microarray) would be useful to examine negative samples. Another possibility is that other infective and non-infective agents could have been present. For example, the previously-mentioned audit of patients presenting at infectious disease units found an alternative non-respiratory diagnosis in \~40% of patients initially clinically diagnosed as having H1N1/2009 \[[@B8]\]. Another explanation could be that a number of samples were actually from the worried well, or from asymptomatic contacts of known or suspected cases of H1N1/2009. An audit similar to the one outlined in the publication above \[[@B8]\] would help to clarify this issue.

It should be noted that the samples examined are representative of our coding protocol and may not be representative of the population at large. Consequently, certain patient groups either with or at risk of severe infection may be over-represented in the final data. Whether or not this is the case, the present study shows that numerous respiratory pathogens were being misdiagnosed as H1N1/2009. The misdiagnosis of H1N1/2009 would have had many undesirable consequences. For example, potentially serious conditions may have been wrongly diagnosed as H1N1/2009 \[[@B8]\]. In addition a large number of individuals are likely to have been unnecessarily treated with oseltamivir \[[@B10]\]. This involves unnecessary cost, and would also have exposed individuals to the side effects of oseltamivir \[[@B11]\]. It should further be noted that there could well have been emotional costs in being wrongly labelled as having \"swine flu\", especially at the early stage of the pandemic, when the severity and outcome of the illness was still largely unknown. In hospitalised patients, unnecessary infection control procedures may have been implemented \[[@B10]-[@B12]\]. Disease surveillance may also have been inaccurate, affecting public health measures and leading to increased panic/concern in the general public.

One way to overcome these issues would be to incorporate a near-patient testing component into the algorithm outlined above. This would no doubt reduce the amount of unnecessary treatment and isolation, and would ensure that surveillance data was more accurate. Such a test would need to be very rapid, sensitive, and specific. Although a number of methods have been described, these can be expensive and - in comparison to PCR-based methods - can be insensitive and non-specific \[[@B13]\]. As a result, PCR methods may be required to investigate influenza negative samples and in low prevalence periods, such as the time period examined in this study, PCR may also be required to confirm positive results.
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